Compare · MRK vs TERN
MRK vs TERN
Side-by-side comparison of Merck & Company Inc. (MRK) and Terns Pharmaceuticals Inc. (TERN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MRK and TERN operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- MRK is the larger of the two at $277.18B, about 45.4x TERN ($6.11B).
- Over the past year, MRK is up 35.3% and TERN is up 1504.2% - TERN leads by 1468.9 points.
- MRK has been more active in the news (20 items in the past 4 weeks vs 6 for TERN).
- MRK has more recent analyst coverage (25 ratings vs 17 for TERN).
- Company
- Merck & Company Inc.
- Terns Pharmaceuticals Inc.
- Price
- $112.17+2.74%
- $52.94+0.03%
- Market cap
- $277.18B
- $6.11B
- 1M return
- -7.19%
- +0.32%
- 1Y return
- +35.33%
- +1504.24%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 20
- 6
- Recent ratings
- 25
- 17
Merck & Company Inc.
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaboration agreement with Gilead Sciences, Inc. to co-develop and co-commercialize long-acting investigational treatment combinations of Lenacapavir and Islatravir in HIV; Amathus Therapeutics to develop treatments for neurodegenerative diseases; and Linnaeus Therapeutics, Inc. to evaluate LNS8801 in combination with KEYTRUDA for patients with advanced cancer. It also has a collaboration with Biomed X Gmbh for building on ongoing research projects in the fields of oncology (DNA damage response and RNA splicing) and autoimmunity (intestinal epithelial barrier in autoimmune diseases); and a collaboration agreement with NGM Biopharmaceuticals, Inc. to focus primarily on the development of novel medicines for unmet patient needs in retinal and CVM diseases, including heart failure. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Terns Pharmaceuticals Inc.
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and other chronic liver diseases. It develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase I clinical trial for the treatment of NASH. The company also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and GLP-1R, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to address metabolic processes involved in the pathogenesis of NASH. Terns Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Foster City, California.
Latest MRK
- EVP, Access, Policy & Comms Guindo Chirfi exercised 1,967 shares at a strike of $110.03 and covered exercise/tax liability with 969 shares, increasing direct ownership by 2% to 61,613 units (SEC Form 4)
- Exe V-P & Pres. MMD Chattopadhyay Sanat exercised 2,597 shares at a strike of $110.03 and covered exercise/tax liability with 1,130 shares, increasing direct ownership by 11% to 15,347 units (SEC Form 4)
- EVP&Pres, Merck Animal Heallth Deluca Richard R. exercised 2,518 shares at a strike of $110.03 and covered exercise/tax liability with 1,241 shares, increasing direct ownership by 0.80% to 161,537 units (SEC Form 4)
- EVP,Chief Info&Digital Officer Williams David Michael exercised 1,377 shares at a strike of $110.03 and covered exercise/tax liability with 679 shares, increasing direct ownership by 2% to 31,716 units (SEC Form 4)
- SVP Fin. - Global Controller Smart Dalton E. Iii exercised 1,408 shares at a strike of $110.33 and covered exercise/tax liability with 483 shares, increasing direct ownership by 11% to 9,137 units (SEC Form 4)
- Executive VP & President, MRL Li Dean Y covered exercise/tax liability with 2,326 shares and exercised 4,722 shares at a strike of $110.03, increasing direct ownership by 3% to 94,431 units (SEC Form 4)
- EVP, General Counsel Zachary Jennifer exercised 2,951 shares at a strike of $110.03 and covered exercise/tax liability with 1,454 shares, increasing direct ownership by 2% to 70,897 units (SEC Form 4)
- EVP, Chief HR Officer Larson Betty D exercised 13,435 shares at a strike of $110.81 and covered exercise/tax liability with 5,858 shares, increasing direct ownership by 122% to 13,774 units (SEC Form 4)
- EVP & CFO Litchfield Caroline exercised 3,935 shares at a strike of $110.03 and covered exercise/tax liability with 1,938 shares, increasing direct ownership by 2% to 92,301 units (SEC Form 4)
- Chairman, CEO & President Davis Robert M exercised 13,300 shares at a strike of $110.03 and covered exercise/tax liability with 6,551 shares, increasing direct ownership by 2% to 450,351 units (SEC Form 4)
Latest TERN
- Amendment: SEC Form 10-K/A filed by Terns Pharmaceuticals Inc.
- Terns Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure
- Terns Pharmaceuticals Announces FDA Breakthrough Therapy Designation Granted to TERN-701 for Certain Patients with Chronic Myeloid Leukemia
- Amendment: SEC Form SC 14D9/A filed by Terns Pharmaceuticals Inc.
- Amendment: SEC Form SC TO-T/A filed by Terns Pharmaceuticals Inc.
- Merck Announces Expiration of Hart-Scott-Rodino Act Waiting Period to Acquire Terns Pharmaceuticals, Inc.
- Merck Begins Tender Offer to Acquire Terns Pharmaceuticals, Inc.
- SEC Form SC 14D9 filed by Terns Pharmaceuticals Inc.
- SEC Form SC TO-T filed by Terns Pharmaceuticals Inc.
- SEC Form 4 filed by Kuriakose Emil